Updates

Announcements

Subscription to raise £2.66 million

Jun 26, 2019

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that it has entered into a subscription agreement with Lanstead Capital Investors LP (“Lanstead”), an institutional investor, together with a related sharing agreement (“Sharing Agreement”), raising approximately £2.66 million. Highlights Subscription for 26,565,200 new ordinary shares of 10 pence each in…
Notice of AGM and posting of Report & Accounts

Jun 4, 2019

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2018, and the Notice of Annual General Meeting has been posted to shareholders. These documents are available, in electronic form, for download on the Company’s website www.immupharma.co.uk ImmuPharma’s…
FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2018

May 24, 2019

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2018 (the “Period”). Key Highlights (including post Period review) Stable financial performance over the Period – Cash balance of £4.9 million (31 December 2017: £2.7 million) – Loss for…
Corporate Update

May 7, 2019

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update on ongoing activities. Lupuzor™ Lupuzor™ is the Company’s late stage asset for Lupus, a potential life threatening auto-immune disease. Following the conclusion of the pivotal Phase III trial in 2018, ImmuPharma continues to look at opportunities which the Board believes over…
Update on Nucant cancer programme

Apr 1, 2019

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update in relation to its discussions with Incanthera Limited (“Incanthera”) on its Nucant cancer programme. Background On 7 September 2018, ImmuPharma announced that it had signed Heads of Terms with Incanthera, a specialist oncology company, and that it had invested £2m into…
IMM March 2019 Corporate Update

Mar 14, 2019

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company today announces a corporate update. Click here to view
Technology review published in Nature Communications

Feb 26, 2019

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce that on 25 February 2019, the peer reviewed research journal ‘Nature Communications’ published a fundamental scientific publication on the proprietary technology Urelix™ from UREkA Sarl (“Ureka”), ImmuPharma’s subsidiary. Ureka, based at the IECB in Bordeaux, France, is carrying out research…
Appointment of NOMAD

Dec 17, 2018

APPOINTMENT OF NOMINATED ADVISOR ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce the appointment of SPARK Advisory Partners Limited (“SPARK”) as the Company’s Nominated Advisor (“NOMAD”), with immediate effect. Commenting on the appointment, ImmuPharma’s Chairman, Tim McCarthy, said: “I am delighted to announce the appointment of SPARK as…
Update on Corporate Activities

Dec 7, 2018

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to provide an update on ongoing activities. Key highlights: Lupuzor™ – Lupuzor™ ‘Managed Access Programme’ – Phase III ‘open label extension’ Nucant (cancer) program: Clinical development collaboration with Incanthera Limited Ureka subsidiary Nominated Adviser status Lupuzor™ Managed Access Programme Lupuzor™ is ImmuPharma’s late…
Nominated Adviser Status

Nov 1, 2018

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, announces that the Directors are aware of the proposed merger of its current nominated adviser (“NOMAD”), Northland Capital Partners (“Northland”) with SP Angel Corporate Finance LLP. The Directors have also been informed that Northland has voluntarily agreed to relinquish its NOMAD status and will…
Interim results announcement for the six months ended 30 June 2018

Sep 26, 2018

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2018 (the “Period”). Key Highlights Lupuzor Lupuzor™ demonstrated a superior response rate over placebo (52.5% vs 44.6% “responders”) in the primary analysis on the Full Analysis Set…
Standford Capital Partners and Si Capital are appointed as joint broker

Sep 19, 2018

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has, with immediate effect, appointed Stanford Capital Partners and SI Capital as joint brokers. They will work in conjunction with Northland Capital Partners who are the Company’s NOMAD and broker. Commenting on the announcement, Tim McCarthy, Chairman of…
IMM September 2018 Corporate Update

Sep 7, 2018

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company today announces a corporate update. Click here to view
2018 Annual General Meeting – All Resolutions Passed

Jun 29, 2018

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.
ImmuPharma announces positive pre-clinical data on its CIDP programme

Jun 14, 2018

Positive results of P140 (Lupuzor™ or Forigerimod) published in the Journal of Autoimmunity in a model of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The T cell modulator P140 significantly reduced the disease in the murine preclinical model Data provides evidence for the expansion of P140 in an autoimmune indication with ‘Orphan Drug Designation’ ImmuPharma PLC (LSE:IMM),…
Annual Report and Accounts Posted to Shareholders

Jun 6, 2018

Notice of Annual general Meeting on 28 June 2018 @ 10.30 AM Venue: Sky Light City Tower, 50 Basinghall Street, London, EC2 ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2017 has been posted to shareholders.…
Further Analysis from its Pivotal Phase III Trial of Lupuzor™ in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort¹

May 29, 2018

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce further analysis of the results from its pivotal Phase III trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, a potentially life threatening auto-immune disease. This new data follows the top-line trial results published on 17 April…
Holding in company

Apr 24, 2018

Download here
Immupharma PLC confident on Lupuzor’s™ future

Apr 23, 2018

ImmuPharma PLC (LON:IMM) CEO Dimitri Dimitriou and Chairman Tim McCarthy discuss with Proactive Investors the top-line results from their phase III trial of the drug Lupuzor™. The data revealed Lupuzor™ was more effective than the placebo (52.5% versus 44.6%) however because the response rate for those taking the non-active medication plus the “standard of care”…
Holding in company

Apr 19, 2018

Download here
Holding in company

Apr 18, 2018

Download here

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

2011 (2)

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MBA

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 30 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr Mauran- Ambrosino obtained her PhD in Chemistry at the Université de Bordeaux as a CIFRE fellow in co-supervision by Dr Goudreau.

She then conducted postdoctoral studies at the “Centre Hospitalier Universitaire” Pellegrin in cell biology. In 2018, she joined Ureka and established the biology department and the analytical chemistry department and in 2021, she became Chief Scientific Officer of Ureka Pharma. Dr Mauran-Ambrosino was a key contributor to the development of BioGlucagon, and BioAMB.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. He then moved back to Canada for one year where he co-founded FindMolecule inc. and worked for the pharma industry.

In 2014 he joined ImmuPharma as research director and established the research laboratories of Ureka in Bordeaux. After the merger of ELRO with Ureka in 2019, Dr Goudreau became Chief Scientific Officer of Ureka Pharma and in 2021, he became Chief Executive Officer of ImmuPharma Biotech. Notably, Dr Goudreau and his team are credited for the discovery and development of, among others, URK 614, BioGlucagon, and BioAMB.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Announcements

Subscription to raise £2.66 million

Notice of AGM and posting of Report & Accounts

FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2018

Corporate Update

Update on Nucant cancer programme

IMM March 2019 Corporate Update

Technology review published in Nature Communications

Appointment of NOMAD

Update on Corporate Activities

Nominated Adviser Status

Interim results announcement for the six months ended 30 June 2018

Standford Capital Partners and Si Capital are appointed as joint broker

IMM September 2018 Corporate Update

2018 Annual General Meeting – All Resolutions Passed

ImmuPharma announces positive pre-clinical data on its CIDP programme

Annual Report and Accounts Posted to Shareholders

Further Analysis from its Pivotal Phase III Trial of Lupuzor™ in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort¹

Holding in company

Immupharma PLC confident on Lupuzor’s™ future

Holding in company

Holding in company

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

2013 (7)

2012 (8)

2011 (2)